We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
77 ELEKTRONIKA

Download Mobile App




AI Technology Allows Neurosurgeons to Identify Brain Tumor Type during Surgery

By HospiMedica International staff writers
Posted on 13 Oct 2023
Print article
Image: AI speeds up identification brain tumor type (Photo courtesy of UMC Utrecht)
Image: AI speeds up identification brain tumor type (Photo courtesy of UMC Utrecht)

When it comes to treating children with tumors in the brain or spinal cord, surgery is often the initial course of action. However, during the procedure, neurosurgeons are typically in the dark about the specific type of tumor and its degree of aggressiveness. A definitive diagnosis is generally not available until a week post-surgery, once the pathologist has thoroughly examined the tumor tissue both visually and molecularly. A breakthrough technology now enables the identification of the tumor type during the surgery itself, within just 1.5 hours, which allows for real-time adjustments to the surgical approach.

Researchers from UMC Utrecht (Utrecht, Netherlands) have come up with a deep-learning algorithm that significantly speeds up the diagnostic process. Leveraging the recently introduced nanopore sequencing technology capable of real-time DNA reading, the researchers have designed an algorithm capable of learning from millions of simulated but realistic DNA sequences. Named 'Sturgeon,' this algorithm can identify the type of tumor in a matter of 20 to 40 minutes, fast enough to alter surgical plans on the fly if needed.

The deep learning algorithm underwent training and validation using a wealth of data from a comprehensive biobank containing tissue samples from children with brain tumors. It was also practically applied multiple times in actual brain surgeries, from the extraction of the tissue sample to determining the type of tumor. Sometimes, a small piece of the tumor tissue is intentionally left behind during surgery to avert neurological complications. If it's later found that the tumor is particularly aggressive, a second surgery may be required, putting additional stress and risks on the patient and their family. This new algorithm eliminates that uncertainty by giving surgeons real-time information about the tumor type.

While the technology is promising, further research is needed to broaden its application. Additional tumor types could be incorporated into the algorithm to meet international standards and enable data comparison. Moreover, outcomes between this new quick method and the current, lengthier one will be compared in collaboration with other domestic and international centers to gauge whether the new technique also enhances patients' quality of life in the long-term.

“It is truly exciting that we have been able to actually make the step into clinical practice by combining all areas of expertise, from basic researchers to pathologists and surgeons. By doing so, we can help surgeons to optimize the outcome of brain tumor surgery,” said Jeroen de Ridder, research group leader within UMC Utrecht.

Related Links:
UMC Utrecht 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Transport Ventilator
TV80

Print article

Channels

Critical Care

view channel
Image: Peerbridge Cor is a 3-lead, 2-channel wireless AECG that simplifies the testing and diagnostic process (Photo courtesy of Peerbridge Health)

First-of-its-Kind Trial to Measure Ejection Fraction Severity Directly from AI-Enabled Remote ECG Wearable

Echocardiograms are a standard diagnostic tool to measure ejection fraction but require a clinical setting for administration. This can pose challenges such as scheduling delays, staffing shortages, accessibility... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more

Business

view channel
Image: The Innovalve transseptal delivery system is designed to enable safe deployment of the Innovalve implant (Photo courtesy of Innovalve Bio)

Edwards Lifesciences Acquires Sheba Medical’s Innovalve Bio Medical

Edwards Lifesciences (Irvine, CA, USA), a leading company in medical innovations for structural heart disease and critical care, has acquired Innovalve Bio Medical LTD. (Ramat Gan, Israel), an early-stage... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.